NY-INVESTABLE-UNIVERSE
The real assets news site Investable Universe announces the launch of Polar Futures , a media series that examines the eight-nation Arctic region’s growing geopolitical importance and its potential for attracting hundreds of billions of dollars in direct investment to develop the region and its bounty of natural resources.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005180/en/
Institutional investors, pension funds and other investors are eyeing the potential of developing infrastructure, shipping, logistics, telecommunications, mining, aquaculture and marine resources and of incubating technologies that aid the transition to renewable energy.
Additionally, new trans-Arctic shipping lanes made more accessible by climate change will focus competing political and military interests on the polar zone.
Nuanced insights from pivotal figures
Against this fluid strategic backdrop, the weekly newsletter and podcast series, curated by editor-in-chief Rebecca Engmann Darst, will feature interviews with pivotal figures in the Arctic discourse, including:
- Greenlandic Minister of Foreign Affairs, Trade, Business and Climate Pele Broberg, on Greenland’s political atmosphere and the new government’s priorities for independence, social welfare and environmental protection
- Ambassador Einar Gunnarsson, who was Chair of the Senior Arctic Officials during Iceland’s chairmanship of the Arctic Council from 2019 to 2021, on Iceland’s role on the council and its recent transition of leadership to Russia
- Leslie Canavera, CEO of PolArctic LLC , an Alaska Native-owned small business, and Chair of the Arctic Economic Council Blue Economy Working Group, on the challenges and opportunities for AI models to support Arctic business and environmental sustainability
- Mac McHale, CRO of Alaskan telecommunications developer Quintillion and a 30-year veteran of broadband development, on the obstacles and potential of the U.S. Arctic telecom infrastructure buildout and how the region offers a test case not only for rugged Earth environments but also for space
- Anne Kirstine Hermann, a Danish journalist and the author of the new book Imperiets Børn (Children of the Empire) , on the legacy of Denmark’s compulsory integration of Greenland in the 1950s, the role of the United Nations and how these complex historical and cultural relationships might affect current and future Arctic development.
The series also will include insights about the roles of Canada, Finland, Norway, Russia and Sweden in the rapidly evolving Arctic zone.
Subscribers will gain exclusive access to nuanced transnational views of the polar investment and geopolitical landscape through a weekly newsletter and podcast interviews with guests from across the diplomatic, media and entrepreneurial spectrum.
Will globalization and climate change spur great-power rivalry in the Arctic?
Noting that research from the Council on Foreign Relations examined the Arctic as a potential site for “the return of great-power rivalry”[1] amid the challenges of globalization and climate change, Darst believes that the Arctic North will be the nexus of a number of conflicts and opportunities in the twenty-first century.
“The polar region’s strategic value is hard to overstate. It holds vast natural and mineral resources and is developing new and high-tech industries in parallel to those riches. Yet in the region, there’s also an intricate tapestry of historical and cultural factors that are rarely discussed on a global level. We will delve unflinchingly into all of them in the newsletter and podcast,” says Darst.
Subscribe to the Polar Futures newsletter and podcast bundle at www.investableuniverse.com/polarfutures .
About Investable Universe
Trofast Media’s Investable Universe provides leading edge insights into investment in real assets, the global “market of things” that spans traditional investments and emerging technologies on earth and in space.
Learn more at InvestableUniverse.com .
[1] https://www.cfr.org/in-brief/whats-stake-rising-competition-arctic
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom